Urologic cancer drugs

Companies developing drugs to treat bladder, kidney and prostate cancer.
−1.2%
over 3 months · S&P 500 −2.1%

Key indicators

Health
51 / 100
Fragile
Solid
Up over 1 year
8 of 12
Volatility
65%
Calm
Choppy
Profitability
−244%
Low
High
Health and price: against the other tags.